Summary. We recently reported a potentiating effect of recombinant human interleukin-l[~ on glucose-stimulated insulin release from the isolated perfused pancreas. With the aim of determining whether the stimulatory effect of recombinant interleukin-l[3 on the B cell in the intact gland was modulated by varying the concentration, time of exposure to recombinant interleukin-l~ or B-cell activity, and to elucidate a possible mechanism of action, we measured in the perfused rat pancreas the release of insulin, glucagon and/or prostaglandin E2 according to the following three different protocols: (1) perfusion with 20 ng/ml of recombinant interleukin-l[3 for 92 min at 5 and 20 mmol/1 D-glucose (2) perfusion with varying concentrations of recombinant interleukin-l[3 ranging from 0.1 • 10 3 ng/ml to 100 ng/ml at 5 and 20 mmol/1 D-glucose (3) perfusion with 20 ng/ml of recombinant interleukin-113 at 5,11 or 20 mmol/1 D-glucose. Furthermore, in a separate set of experiments we examined the influence of the cytokine on the morphology of the endocrine pancreas. Interleukin-l[~ stimulated insulin secretion at 11 and 20 mmol/1 D-glucose and potentiated first as well as second phase insulin release in a dose-dependent fashion, with decreasing effect at higher concentrations. Glucagon secretion was also stimulated by recombinant interleukin-l[3, irrespective of increasing glucose (5, 11, 20 retool/l) and insulin concentrations. The potentiating effect of recombinant interleukin-l[3 on insulin secretion was evident even after discontinued perfusion with the cytokine, suggesting a priming effect on B-cell function. Furthermore, we did not observe any relation between the recombinant interleukin-113 mediated insulin and glucagon release and prostaglandin E2. Electron microscopy of the pancreata perfused with recombinant interleukin-l~ revealed significant B cell and to a lesser extent A-cell lysis as well as induction of cell protrusions ("blebs") in B cells only, accompanied by peripheral degranulation and rearrangement of rough endoplasmatic reticulum. We suggest that in addition to a paracrine effect of locally produced interleukin-l[3 systemic interleukin-l[3 may have an endocrine effect on A-and B-cell function and viability. Interleukin-l[3 should be considered to be a physiological modulator of insulin and glucagon secretion e.g. during the acute phase response, but also as a pathogenetic factor in Type i (insulin-dependent) diabetes mellitus.
Interleukin-1 (IL-1) is a family of 17.3-17.5 kilodalton (kD) peptides mainly produced by activated cells of monocytic/phagocytic lineage (macrophages and natural killer cells), but also by parenchymal cells, such as endothelial cells, renal mesangial cells and astrocytes [1] . The acute phase response seems to be induced primarily by ILl and tumour necrosis factor alpha, (TNF) [1] . Recently, it was demonstrated that IL-1 is distributed throughout the peripheral nervous system innervating several organs [2] .
Many of the proposed in vivo effects of IL-1 have been confirmed by in vitro studies. We have reported that recombinant IL-1 (rIL-1), as well as native IL-1, selectively affects pancreatic B-cell activity: stimulation of insulin secretion followed by inhibition and B-cell cytotoxicity [3] , dependent on the period of incubation, dose of rIL-1 and degree of metabolic activity of the B cells [4] , and we have hypothesized that IL-1 produced in the islets mediates a paracrine destruction of B cells eventually leading to Type 1 (insulin-dependent) diabetes mellitus [5] . The acute phase response is accompanied by increased levels of systemic IL-1 [1] and an endocrine effect on insulin and glucagon secretion from the pancreas may be possible. However, if physiological and pathophysiological actions of circulating IL-1 on the endocrine pancreas are to be studied, islets in organ culture may not be an ideal model for the endocrine pancreas, since the function of the endocrine cells may be affected by the isolation and culture procedures, and since nutrients and other substances do not reach the endocrine cells via their physiological route from B to A to D cells [6] . In the islets in the isolated perfused pancreas the endocrine cells can be exposed to substances via the normal vascular supply, and the action of the substance studied without the influence of neuronal or humoral factors.
We have previously reported that recombinant interleukin-l[3 (rIL-l~) potentiates glucose-stimulated insulin release [7] . The aim of this study was to test whether riLl[3 influences islet cell morphology in the perfused rat pancreas and to achieve further insight into the stimulatory effect of rIL-113 on insulin, glucagon and prostaglandin E2 (PGE2) release in relation to time, dose, glucose concentration and a possible mechanism of action.
Materials and methods

Animals
Male Wistar rats, purchased from Mr (Lille Skensved, Denmark), were housed in our laboratory under controlled conditions of light, temperature and humidity for approximately 10 days before the experiments were performed. The rats were given water and standard chow (Altromin, Chr.Petersen A/S, Ringsted, Denmark) ad libitum. All experiments were initiated between 09.00 and 11.00 hours.
Pancreas perfusion
Fed rats (body weight 210-220 g) randomly allocated to perfusion with either rIL-113 or 0.9% NaC1, were anaesthetized by i.p. injections of sodium pentobarbital (50 mg/kg). The preparation of the isolated pancreas was performed as described by Svenningsen et al. [8] . The in situ pancreas was placed in a 37~ prewarmed chamber and was perfused through the celiac trunk and the superior mesenteric artery with a Krebs-Ringer-Bicarbonate buffer (KRB) supplemented with 20 mmolfl Hepes (KRBH) and 4% (weight/volume) bovine serum albumin (fraction V, Miles Laboratories Inc., Elkhart, Ind., USA), filtered, heated to 37~ before perfusion and kept at 37~ in the perfusate reservoirs. The KRBH was gassed with 95% 02/5% CO2 before and during the perfusion to maintain pH 7.4 and to supply the organ with oxygen. The venous effluent was collected on ice after a single passage of the pancreas. Sampling was performed at 3-min intervals, except after a change in glucose concentration, where sampling took place at l-rain intervals. The perfusion rate was held constant at 3 ml/min. After isolation of the pancreas, the organ was subjected to an equilibration period of 20 min according to the different experimental protocols. Data from this period were not included in the evaluation of the experiments. Baseline samples were collected from time zero to 12 min. From 12 min to 72 min (except in protocol I) 0.9% NaC1 or rIL-113 was added to the perfusate reservoirs in a blinded design according to the protocols (see below). Perfusion experiments not fulfilling the following technical criteria: ischaemia time less than 3 min, perfusion pressure less than 60 mm Hg, no oedema, continuous gastric secretion or continuous peristalsis of the duodenum, were excluded from the analysis.
Preparation of rlL-1
Human rIL-l[3 (R-007) was expressed in Escherichia coli and corresponded to the amino acid sequence 11~269 (17 kD) of the pI 7 beta form of the natural IL-113 [9] . One unit of rIL-l[3 corresponded to 0.1 ng of protein.
The morphology experiments were performed L. D. Wogensen et al.: Interleukin-lf3 and pancreatic hormone release with rIL-l[3 from two different sources; R-007 and B-44. B-44, supplied by Nordisk Gentofte A/S, (Gentofte, Denmark), was also expressed in E. coli and corresponded to the 153 amino acid, pI 7 beta form of the native IL-I~3 with the N-terminal amino acid being alanine [10] . The biological activity as estimated in the C3H/HeJ mouse thymocyte co-stimulatory assay was 300 WHO U/ng. Both batches ofrIL-l[3 were known to be active when tested on isolated islets. From isolated rat islets inhibition of insulin release was obtained with 100 pg/ml ofrIL-l[3 R-007 and 37 pg/ml of rIL-113 B-44.
Hormone assay
Rat insulin was determined by a RIA using a guinea pig anti-porcine-insulin serum and 125I porcine 14aminoiodoinsulin as tracer (Nordisk Gentofte A/S). Rabbit anti-guinea pig immunoglobulin (Dakopatts, Denmark) was used to precipitate insulin-anti-insulin complexes, separating bound from free tracer. Rat insulin was used as standard (Novo Industry A/S, Bagsvaerd, Denmark). Non-specific binding was 0.3 _+ 0.06%, n = 13. The coefficient of variation of independent replicates was 9.3 +0.5%, n = 39. All samples were diluted to a concentration between 0.02 and 0.8 nmo!/i, in which interval the standard curve showed tinearity to serial dilutions. The detection limit was 0.01 nmol/1.
Glucagon was determined utilizing reagents in a commercially available RIA kit (Novo Biolabs, B agsvaerd, Denmark). Pork glucagon was used as standard. All samples were analysed undiluted. The coefficient of variation of independent replicates was 8.3 +_ 0.9%, n= 9. Non-specific binding was 4.6+0.31%, n = 9. The detection limit of the RIA was 4.0 pmol/1.
PGEz was measured by RIA. The RIA previously described [11] and evaluated in control studies by gas chromatography-mass spectrometry [12] included a Sephadex LH-20 chromatographic step which was omitted in the present RIA. Comparison of the original (x) and the modified RIA (y) by regression analysis gave a correlation coefficient (r) of 0.995. The detection limit of the present RIA was 20 pg PGE2/ml of sample. The intra-and interassay coefficients of variation was 1.2-3.7% and 3.6-6.3%, respectively, in the range 0.100 pg/ml, n = 16. (Table 1) . Previous studies of rIL-l[3 in the perfused pancreas employed a perfusion time of 60 min [7] . With the purpose of investigating the effect of prolonging the exposure time to the cytokine to 92 rain, pancreata were perfused with rIL-l[3 (20 ng/ml, n = 5) or 0.9% NaC1 (n = 3) in the 20 min equilibration period and from 0 to 42 min at 5 mmol/1 D-glucose and from 43 to 72 rain at 20 mmol/1 D-glucose. Each fraction was analysed for insulin. (n = 7) or 100 ng/ml (n = 5) ) or 0.9% NaC1 (n = 17) was added to the perfusate from 13 to 72 rain. Each fraction of effluate was analysed for insulin. (Fig. 1, 2 (Table 3 and Fig. 4 a, b, and c). Nine pancreata were per• during the equilibration period and from 0 to 42 min with KRBH containing 5 mmol/1 of Dglucose and from 43 to 72 rain with KRBH containing 20 retool/1 Dglucose. From 12 to 72 rain 0.9% NaC1 (n = 4) or rlL-1]3 (20 ng/ml of R-007, n = 3 or 15 ng/ml of B-44, n = 2) was added to the perfusate reservoirs in a blinded design. At the end of the experimental period the pancreata were per• with 25 ml 1% glutaraldehyde in natriumcacodylate buffer, pH 7.2. The fixed pancreata were removed, the spleen-near part dissected and cut into 3 mmx 3 mm pieces while bathed in the buffered glutaraldehyde. After further fixation for i h at 4~ in 1% glutaraldehyde, tissue pieces were washed and postfixed with cacodylate buffered OsO4 (1.5%) for 2 h. Specimens were washed 3 times in cacodylate buffer and were stored in this buffer for a maximum of 10 days. After dehydration with graded ethanol dilutions the tissue was embedded in epoxy resin according to Spurr [13] . All specimens were sectioned semi-thin and screened for islets after staining with toluidine blue, islet containing tissue was sectioned ultra-thin. For quantitation of lysis events, on micrographs at a final magnification of 5000 x, the number of A and B cells was counted. Lysis was regarded as positive when cytoplasm did not exhibit the usual intermediate contrast but stained opaque. Lysis was additionally confirmed by screening the respective islet cells at higher magnifications for disrupted plasma membrane.
Experimental protocols I The effect of time
III The effect of glucose concentration
IV Islet morphology at ultrastructural level
Statistical analysis
Results are expressed as means • SEM. In protocol III the hormone release from 12 to 72 rain was calculated as the increase in hormone release above mean pre-infusion level (average of baseline level in the particular experiment). The two-tailed Mann-Whitney rank sum test was used to test differences between two groups of rats. The Kruskall-Wallis test of variance was used when comparing more than two groups of unpaired data (protocol II). The Friedman test of variance was used when comparing more than two groups of paired data (protocol III). Chi-squared test was used in the morphology study. The level of significance chosen was 5%.
Results
The effect o]:92 min of exposure to rIL-l~ on D-glucose-induced insulin release
rIL-l~ caused a transient increase in insulin release from 0 to 42 min, not observed in control pancreata (data not shown), causing a higher total release of insulin from 0 to (Table 1) . Both groups exhibited a biphasic insulin release in response to 20 mmol/1 of D-glucose. However, insulin release during first and second phase was significantly higher (p < 0.05) in the rIL-1[3 perfused group of pancreata compared to the control group.
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All groups showed identical and stable insulin baseline levels from 0 to 24 min and exhibited first as well as second phase insulin release in response to 20 mmol/1 of D-glucose ( Table 2 ). The potentiating effect of rIL-l[3 on glucose-stimulated insulin release was dependent on the concentration of the cytokine in the perfusate buffer (first phase: p < 0.005, second phase: p < 0.005, Kruskall Wallis test of variance). However, at concentrations exceeding 14 ng/ml the second phase insulin release declined, indicating a bimodal effect of rlL-l[3 on glucose-stimulated insulin release. At the two lowest concentrations of rlL-l[3, first as well as second phase insulin release was decreased. However, this decrease was not statistically significant.
The influence of glucose concentration on the potentiating effect of rIL-l[3 on stimulated insulin release
The baseline concentration of insulin in rIL-l[3 perfused pancreata and in the control group was identical at 5, 11 and 20 mmol/1 of D-glucose. At 5 mmol/1 of D-glucose (0 to 72 min) no significant difference in insulin release was observed comparing rIL-l[3 (n = 6) and 0.9% NaC1 (n = 7) perfused pancreata. Stimulation with 11 mmol/1 D-glucose induced the characteristic first and second phase insulin release in both groups. The amount of insulin released during the first phase (73 to 78 min) was 6.5 + 1.1 pmol in the rIL-l[3-treated group and 2.2 + 0.7 pmol in the control group (p < 0.05) and during the second phase (79 to 84 min) 9.0 + 2.2 pmol and 2.5 + 0.7 pmol, respectively (p < 0.05) (Fig. 1 a) . At 11 and 20 mmol/1 of D-glucose a steady increase in insulin secretion was observed from 12 to 72 min in the control groups (p < 0.005, n = 8, p < 0.0005, n = 8). However, rIL-l[3 induced a more pronounced release of insulin at both glucose concentrations (p < 0.0005, n = 12, p < 0.0005, n = 7, respectively) ( Fig. 2 a  and 3 a) . At 11 retool/1 of D-glucose rIL-113 induced a significantly higher insulin level in the period from 42 to 72 min (p < 0.01 at each time point) and the insulin released above the baseline level was 42 + 10 pmol compared to 0.4 +4.8 pmol in the control group (p < 0.01). However, the total amount of insulin released from 13 to 72 rain in the two groups did not differ significantly (riLl[3: 75.4 + 11.2 pmol, control: 49.8 + 12.7 pmol, p = 0.10) (Fig. 2 a) . (Fig.3 a) . Lowering the D-glucose concentration from 11 or 20 mmol/1 caused a rapid, physiological decrease in insulin release in all groups. At 5 and 11 mmol/1 of D-glucose rIL-l[3 and 0.9% NaC1 perfused pancreata exhibited stable and identical baseline levels of glucagon from 0 to 12 min (p > 0.05). At 20 mmol/1 of D-glucose the glucagon baseline level in the control group was higher than in the rIL-l[3 group (p < 0.005). This could be explained by an increased glucagon release secondary to a lower insulin level (Fig. 3 b) [6]. However, the difference in insulin secretion between to 84 min-from rat pancreata perfused with 20 ng/ml of recombinant interleukin-l~3 (n = 7) ( 9 ) or 0.9% NaC1 (n = 8) ( 9 from 12 to 72 rain (Protocol III) group was unaffected by the change in glucose concentration (Fig. 1 b) . At 11 and 20 mmol/1 D-glucose a significant increase in glucagon release was observed exclusively in the rIL-l~3 perfused pancreata (p <0.0005), although no difference in glucagon level was observed between the control and the rlL-l[~ perfused pancreata at each glucose level (p > 0.05) (Fig.2 b and 3 b) . All groups responded with an accentuated glucagon release in re-sponse to 5 mmol/1 D-glucose in the interval from 73 to 84 min. During perfusion with 5 mmol/1 of D-glucose the baseline level of PGE2 at 6 min was 0.06 + 0.027 ~tg/1 in control experiments compared to 0.14 + 0.015 gg/1 in rIL-l[3 perfused pancreata (p<0.05). A marked increase in PGE2 release was observed in both groups, (rIL-l[3: p < 0.0005, control: p < 0,0005). The rIL-l[3 co-perfused pancreata exhibited at each time point a statistically significant highe r level of PGE2 in the effluate compared to the control group (0.001 <p <0.02) (Fig.1 c) . At 11 and 20 mmol/1 of D-glucose the baseline level of PGE2 in 0.9% NaC1 and rIL-1[3 perfused pancreata was identical (p > 0.05) and all groups exhibited a significant increase in PGE2 release during the perfusion (Fig. 2 c and 3 c) , but no significant differences between the two groups were demonstrable at any given time during perfusion with 11 or 20 mmol/1 of D-glucose.
Islet morphology at the ultrastructural level
Electron microscopic examination of islets in situ after rIL-l[~ perfusion (5pancreata) revealed a significant amount of islet cell lysis as compared to 0.9% NaC1 perfused control pancreata (n = 4) ( Table 3) . Lysis was evident as disrupted plasma membranes and considerably lower staining of cytoplasm. For quantitation of lysis the number of cells in islet sections was determined and individual cells screened for intactness. Lysed cells still contained typical A-and B-cell granules (Fig. 4 a and b) . The lower or absent cytoplasm stain differs from the increased cytoplasm staining regularly seen in necrotic cells [14] . In four 0.9% NaC1 perfused glands 34 islets were identified and a total of 1553 cells counted. In five rIL-l[3 perfused glands the numbers were 31 islets and 1882 cells, respectively. As seen in Table 3 , a small number of A as well as B cells were lysed in the 0.9% NaC1 perfused control pancreata. Perfusion with rIL-l[3 resulted in increased lysis of all cell types, with a relatively higher increase of B-cell lysis than of A-cell lysis (p < 0.01). Still intact B cells of rIL-l[3 perfused pancreata often exhibited unique cell protrusions, such a "bleb" was formed by a peripheral part of the B-cell cytoplasm, rarely contained insulin granules and exhibited a typical rearrangement of rough endoplasmatic reticulum (rER) membranes (Fig. 4 a and b) . "Bleb" formation was never seen on A cells and only on 5 B cells surrounding a capillary in one islet of the 0.9% NaC1 perfused pancreata (in 6 of 1012 cells counted). 
Discussion
Peripheral hyperinsulinaemia and hyperglucagonaemia are observed after i.v. administration of bacterial endotoxin to rats [15] and insulin secretion from perfused pancreata isolated from rats treated with endotoxins in vivo is enhanced [16] . However, co-perfusion with endotoxin does not affect insulin secretion from the isolated pancreas [17] . These observations imply the existence of a secondary agent, linking endotoxin to pancreatic hypersecretion. Among other effects, endotoxins induce production of IL-1 from macrophages [1] , and treatment of rodents in vivo with culture supernatants from macrophages [18] or with rIL-1 [19, 20] induces hyperinsulinaemia and hyperglucagonaemia, as well as enhanced release of the two hormones from the glucose-stimulated isolated pancreas [18, 21] . In the intact perfused rat pancreas we observed a concentration-dependent, stimulatory effect of rIL-113 on insulin release from the glucose-stimulated B cell, accompanied by stimulation of glucagon secretion, suggesting the existence of an endocrine effect of systemic IL-I[~ on A-and B-cell function in addition to the previously hypothesized local effect of IL-1 [3] . The observations of the present study support the hypothesis that hyperinsulinaemia and hyperglucagonaemia observed after endotoxin treatment and during the acute phase response [1] are mediated by an endocrine effect of IL-1 directly on the pancreatic A and B cell, indicating that IL-1 is the link between endotoxin and pancreatic hypersecretion in vivo. The concentration of systemic IL-1 during endotoxin infusions or severe infectious diseases have been reported to vary from 0.500 ng/ml [22] to 1.5 ng/ml [23] . The concentrations in our experiments are high, but because the cytokines adhere to proteins, the fraction of biologically active rIL-l[3 reaching the islet cells is unknown.
Our observations on the intact pancreas are identical to described effects of the cytokine on isolated islets during short-term exposure to rIL-1[3 ( < 6 h) [24] . Inhibition of insulin release as observed with isolated islets exposed to rIL-113 for more than 6 h [3] was not seen. Prolongation of rIL-l[3 exposure time from 60 min, as described in our previous paper [7] , to 92 min, did not convert the potentiating effect on glucose-stimulated insulin release to inhibition. However, the dose-dependent stimulatory effect of rlL-l[3 exhibited a tendency towards a biphasic effect on second phase insulin release (Table 1 ). This observation could be explained by an inhibitory effect of rIL-l[3 at a high glucose concentration, starting to become apparent after perfusion for a longer period with higher concentrations of the cytokine ( > 14 ng/ml).
This shift from stimulation to inhibition of insulin release by rIL-l~ is supported by the morphological findings, which showed that 20% of the B cells were lysed and that the intact B cells were undergoing changes, as indicated by "bleb" formation. "Bleb" formation may be an early stage of cell death, as shown for TNF-induced cytolysis in fibroblast cells, in which the "bleb" formation is caused by destruction of the cytoskeleton, preceding lysis of the plasma membrane [25] . "Bleb" formation was not observed on isolated islets exposed to rIL-l~ in vitro, but dilatation and derangement of the rER and B-cell lysis was found [26, 27] . However, B-cell lysis was more extensive in isolated islets [26] . We suggest that the effect of riLl[3 on the perfused pancreas is heterogenous, dependent upon the flow through the perfused pancreas influencing the amount of rIL-l[3 reaching the islets. Furthermore, the effect is dependent upon the B-cell activity, in that the working cell is more sensitive than the resting cell [28] , although very high glucose concentrations (i. e. higher than 22 mmol/1) are protective [3, 27] . This is very pertinent as the B cell population in the pancreas is heterogenous, consisting of a mixed population of resting and active cells [29] . Based on the morphological findings we believe that further prolongation of rIL-l[3 perfusion leads to inhibition of insulin release. However, duration of the experiments are limited by the viability of the in vitro perfused pancreas and pre-treatment in vivo for a longer period may be necessary for induction of inhibited insulin secretion [30] .
Glucagon secretion was suppressed at all three D-glucose levels. This observation is not surprising, since the threshold for suppression of glucagon release is < 2.5 mmol/1 glucose and because maximum suppression of glucagon release is obtained at 6-11 mmol/1 of D-glucose [31] . rIL-l[3 induced a distinct stimulation of glucagon secretion at 5 mmol/1 D-glucose and in spite of increasing insulin and D-glucose concentrations, rIL-l[3 induced a statistically significant increase in glucagon secretion at 11 and 20 mmol/1 of D-glucose as well (p < 0.0005). Furthermore, the rIL-l~ stimulated glucagon secretion at 5 mmol/1 of D-glucose could not be suppressed by an elevated glucose concentration from 72 to 84 min, in spite of discontinued rIL-113 perfusion, indicating that the sensitivity of A cells to glucose is changed by exposure to rIL-1~3, making them unresponsive to an increase in glucose concentration. For comparison, rIL-l~3 potentiated first and second phase insulin release in response to a shift in D-glucose concentration from 5 to 11 mmol/1 in spite of discontinued rIL-113 co-perfusion at 72 min, suggesting that the B cells are hyperresponsive after exposure of riLl[3 to D-glucose, as known for pancreata isolated from endotoxin-treated rats [15] and isolated islets after rlL-l~ perifusion [32] . The stimulatory effect of rIL-l[3 on glucagon secretion at 11 and 20 mmol/1 D-glucose may be blunted by a counter-acting A-cell inhibitory effect mediated by an increased insulin secretion, since it is known from experiments on the perfused pancreas that the order of islet cellular perfusion and functional interaction is from B to A to D cell [6] . However, these experiments do not rule out a paracrine regulation of islet hormones through the interstitial fluid spaces.
rIL-1J3 induces production of POE2 from fibroblasts, muscle cells and endothelial cells [1] and rIL-l[3 stimulated cortisone release from the perfused adrenal is blocked by the cyclooxygenase inhibitor indomethacin [33] . Furthermore, since arachidonate metabolites -e. g. prostaglandins -may participate in glucose-stimulated insulin release [34, 35] and epinephrine/norepinephrinestimulated glucagon secretion [36] , accordingly a prostaglandin-mediated stimulatory effect of rIL-l[3 on insulin and glucagon secretion was possible. However, we observed an increasing PGE2 release throughout the perfu-L. D. Wogensen et al.: Interleukin-lJ3 and pancreatic hormone release sion period in both 0.9% NaC1 and in rIL-l[3 perfused pancreata and only at 5 mmol/1 D-glucose did co-peffusion with rIL-l[3 induce a higher release of the arachidonate metabolite. The major part of the released PGE2 probably originates from the exocrine tissue and, e.g., endothelial cells and platelets trapped in the tissue preparation.
In conclusion, the acute effect of rIL-113 on the intact perfused pancreas is characterized by stimulation of insulin and glucagon secretion, dependent upon rIL-1 [3 concentration and D-glucose level, with a tendency towards a bimodal effect, accompanied by induction of ultramorphological changes predominately in the B cells. We hypothesize that IL-113 in vivo may have an endocrine effect directly on the pancreas influencing A-and B-cell function and structure and should be investigated, not only as a physiological modulator of insulin and glucagon release, e.g. during the acute phase response, but also as a pathogenetic factor in Type 1 (insulin-dependent) diabetes mellitus in predisposed individuals.
